XZP-3621 + itraconazole

XZP-3621 is an orally administered, next-generation small molecule dual inhibitor targeting anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (ROS1). It binds to and inhibits the activity of ALK and ROS1 tyrosine kinases, disrupting their signaling pathways and inhibiting cell growth in tumor cells expressing these targets. The drug is primarily being developed for the treatment of non-small cell lung cancer (NSCLC), particularly in patients with ALK or ROS1 rearrangements. Xuanzhu Biopharmaceutical is developing XZP-3621, which has reached phase III clinical trials for NSCLC and earlier phases for other cancers such as small cell lung cancer and lymphoma[2][4][6]. Itraconazole is a well-established antifungal agent that acts by inhibiting fungal cytochrome P450-dependent enzyme lanosterol 14α-demethylase; it is not related mechanistically to XZP-3621 but may be co-administered in some settings.